Pharmaphorum
The FDA’s cancer drugs committee backs AstraZeneca’s Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.
Pharmaphorum
The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.
Pharmaphorum
The FDA’s cancer drugs committee backs AstraZeneca’s Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.